ADHD Therapeutics Markets to Show Strong Growth, Expects GBI Research14 Jun 2013 • by Natalie Aster
The impending publication of the fifth edition of the American Psychiatric Association's (APA) Diagnostic and Statistical Manual of Mental Disorders (DSM-V) may affect diagnosis rates of conditions such as Attention-Deficit/Hyperactivity Disorder (ADHD), both in the US and worldwide.
European countries are increasingly adopting the US diagnostic criteria (DSM-IV), resulting in more and more diagnoses of ADHD. This may eventually result in a rise in ADHD diagnoses even further afield.
Although Europe trails behind the US in terms of market revenue, ADHD therapeutics markets are expected to show strong growth, with Spain predicted to witness a Compound Annual Growth Rate (CAGR) of 8% over 2012-2018, beating the US CAGR of 6% during the same future period. European markets have not yet neared the saturation point that ADHD therapeutics are facing in the US, and there is an optimistic view for ambitious growth in this region. The ADHD therapeutics market across France, Germany, Italy, Spain and the UK is predicted to reach approximately $182m in 2018.
In-demand report "ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment" by GBI Research provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment
Published: April, 2013
Price: US$ 3,500.00
More information can be found in the report “ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment” by GBI Research.
To order the report or ask for sample pages contact firstname.lastname@example.org